Pembrolizumab (another anti-PD-1 monoclonal antibody) is registered for the second line treatment in locally advanced and advanced NSCLC patients with PD-L1 expression on ≥1% of tumor cells, and for the first line treatment in metastatic NSCLC patients with PD-L1 expression on ≥50% of cancer cells. The gene discussed is CD274; the disease is non-small cell lung carcinoma.